Non-randomized studies using causal-modelling may give different answers than RCTs: a meta-epidemiological study.

[1]  J. Ioannidis,et al.  Marginal structural models and other analyses allow multiple estimates of treatment effects in randomized clinical trials: Meta-epidemiological analysis. , 2019, Journal of clinical epidemiology.

[2]  L. Hemkens.  How Routinely Collected Data for Randomized Trials Provide Long-term Randomized Real-World Evidence. , 2018, JAMA network open.

[3]  Correction notice to paper “Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey” , 2018, British Medical Journal.

[4]  J. Ioannidis,et al.  Routinely collected data for randomized trials: promises, barriers, and implications , 2018, Trials.

[5]  S. Goodman,et al.  Using Design Thinking to Differentiate Useful From Misleading Evidence in Observational Research. , 2017, JAMA.

[6]  Julian P T Higgins,et al.  Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. , 2017, Epidemiology.

[7]  R. Lewis,et al.  Confounding by Indication in Clinical Research. , 2016, JAMA.

[8]  M. Hernán,et al.  ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions , 2016, British Medical Journal.

[9]  J. Ioannidis,et al.  Agreement of treatment effects for mortality from routinely collected data and subsequent randomized trials: meta-epidemiological survey , 2016, British Medical Journal.

[10]  K. Polkinghorne,et al.  Intensive Hemodialysis and Mortality Risk in Australian and New Zealand Populations. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  Maria Laura Luchetta,et al.  Deviation from intention to treat analysis in randomised trials and treatment effect estimates: meta-epidemiological study , 2015, BMJ : British Medical Journal.

[12]  Robert D Gibbons,et al.  Antidepressant treatment and suicide attempts and self‐inflicted injury in children and adolescents , 2015, Pharmacoepidemiology and drug safety.

[13]  K. Lapane,et al.  Application of marginal structural models in pharmacoepidemiologic studies: a systematic review , 2014, Pharmacoepidemiology and drug safety.

[14]  L. Bero,et al.  Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials. , 2014, The Cochrane database of systematic reviews.

[15]  L. Trinquart,et al.  Comparison of Treatment Effect Estimates From Prospective Nonrandomized Studies With Propensity Score Analysis and Randomized Controlled Trials of Surgical Procedures , 2014, Annals of surgery.

[16]  Lilia R. Lukowsky,et al.  Comparing mortality of peritoneal and hemodialysis patients in the first 2 years of dialysis therapy: a marginal structural model analysis. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[17]  Roger Logan,et al.  Observational data for comparative effectiveness research: An emulation of randomised trials of statins and primary prevention of coronary heart disease , 2013, Statistical methods in medical research.

[18]  Y. Yazdanpanah,et al.  Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study , 2012, PloS one.

[19]  K. Armstrong.  Methods in comparative effectiveness research. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Bhandari,et al.  Confounding: what is it and how do we deal with it? , 2012, Canadian journal of surgery. Journal canadien de chirurgie.

[21]  M. Marshall,et al.  Comparison of Outcomes by Modality for Critically Ill Patients Requiring Renal Replacement Therapy: A Single-Centre Cohort Study Adjusting for Time-Varying Illness Severity and Modality Exposure , 2012, Anaesthesia and intensive care.

[22]  M. Hernán,et al.  Beyond the intention-to-treat in comparative effectiveness research , 2012, Clinical trials.

[23]  E. Porrini,et al.  Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  O. Kuss,et al.  Treatments effects from randomized trials and propensity score analyses were similar in similar populations in an example from cardiac surgery. , 2011, Journal of clinical epidemiology.

[25]  X. Basagaña,et al.  Differences Between Marginal Structural Models and Conventional Models in Their Exposure Effect Estimates: A Systematic Review , 2011, Epidemiology.

[26]  James M Robins,et al.  When to Initiate Combined Antiretroviral Therapy to Reduce Mortality and AIDS-Defining Illness in HIV-Infected Persons in Developed Countries , 2011, Annals of Internal Medicine.

[27]  Sherri Rose,et al.  Implementation of G-computation on a simulated data set: demonstration of a causal inference technique. , 2011, American journal of epidemiology.

[28]  Yi-Wen Chiu,et al.  Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. , 2011, Archives of internal medicine.

[29]  Michael Rosenblum,et al.  Marginal Structural Models , 2011 .

[30]  K. Polkinghorne,et al.  Home hemodialysis and mortality risk in Australian and New Zealand populations. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  G. Heinze,et al.  Mycophenolate Mofetil Use Is Associated With Prolonged Graft Survival After Kidney Transplantation , 2009, Transplantation.

[32]  Antti Tanskanen,et al.  11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study) , 2009, The Lancet.

[33]  Bryan R Luce,et al.  Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change , 2009, Annals of Internal Medicine.

[34]  S. Knight,et al.  Mycophenolate Mofetil Decreases Acute Rejection and may Improve Graft Survival in Renal Transplant Recipients When Compared with Azathioprine: A Systematic Review , 2009, Transplantation.

[35]  Samy Suissa,et al.  Traditional versus marginal structural models to estimate the effectiveness of β‐blocker use on mortality after myocardial infarction , 2009, Pharmacoepidemiology and drug safety.

[36]  Tyler J. VanderWeele,et al.  Marginal Structural Models for the Estimation of Direct and Indirect Effects , 2009, Epidemiology.

[37]  R. Wolfe,et al.  The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  G. Heinze,et al.  Statin use is associated with prolonged survival of renal transplant recipients. , 2008, Journal of the American Society of Nephrology : JASN.

[39]  Stephen R Cole,et al.  Constructing inverse probability weights for marginal structural models. , 2008, American journal of epidemiology.

[40]  E. Delaporte,et al.  Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. , 2008, AIDS research and human retroviruses.

[41]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[42]  M. J. van der Laan,et al.  Virologic efficacy of boosted double versus boosted single protease inhibitor therapy , 2007, AIDS.

[43]  C. Roberts,et al.  Suicidal behaviour in youths with depression treated with new-generation antidepressants: meta-analysis. , 2006, The British journal of psychiatry : the journal of mental science.

[44]  J. Robins,et al.  Estimating causal effects from epidemiological data , 2006, Journal of Epidemiology and Community Health.

[45]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.

[46]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[47]  James M. Robins,et al.  Association, Causation, And Marginal Structural Models , 1999, Synthese.

[48]  Douglas G Altman,et al.  Statistical methods for assessing the influence of study characteristics on treatment effects in ‘meta‐epidemiological’ research , 2002, Statistics in medicine.

[49]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[50]  J. Robins,et al.  Marginal Structural Models to Estimate the Joint Causal Effect of Nonrandomized Treatments , 2001 .

[51]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[52]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[53]  James M. Robins,et al.  Marginal Structural Models versus Structural nested Models as Tools for Causal inference , 2000 .

[54]  J. Robins,et al.  Estimation of the Causal Effect of a Time-Varying Exposure on the Marginal Mean of a Repeated Binary Outcome , 1999 .

[55]  H. Davies,et al.  When can odds ratios mislead? , 1998, BMJ.

[56]  J M Robins,et al.  Correction for non-compliance in equivalence trials. , 1998, Statistics in medicine.

[57]  J. Ioannidis,et al.  A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. , 1996, Archives of internal medicine.

[58]  W. Richardson,et al.  The well-built clinical question: a key to evidence-based decisions. , 1995, ACP journal club.